Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quest Diagnostics (DGX)

Quest Diagnostics Q1 revenue up 9.2%, EPS up 15.5%; raises 2026 guidance

Positive Impact 4 of 5 earnings Written later

Quest Diagnostics reported first quarter 2026 net revenues of $2.90 billion, up 9.2% from a year earlier, and reported diluted EPS of $2.24, up 15.5%. The company raised its full year 2026 revenue and EPS guidance, which means higher expected results for shareholders than the prior outlook.

Key points

  • Q1 2026 net revenues were $2.90 billion, up 9.2%; Diagnostic Information Services revenues rose 9.4% to $2.83 billion
  • Q1 reported diluted EPS was $2.24, up from $1.94; adjusted diluted EPS was $2.50, up 13.1% from $2.21
  • Full year 2026 reported diluted EPS guidance was raised to $9.58 to $9.78 from $9.45 to $9.65; adjusted EPS guidance to $10.63 to $10.83 from $10.50 to $10.70
  • Cash provided by operations fell 11.6% to $278 million in Q1 from $314 million

The filing

CompanyQuest Diagnostics (DGX)
Form8-K, current report
Filed with the SECApr 21, 2026, 6:48 AM ET
Accession number0001022079-26-000040

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.